Allspring Global Investments Holdings LLC Has $45.11 Million Holdings in Natera, Inc. (NASDAQ:NTRA)

Allspring Global Investments Holdings LLC grew its position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 28.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 720,160 shares of the medical research company's stock after buying an additional 159,993 shares during the quarter. Allspring Global Investments Holdings LLC owned 0.60% of Natera worth $45,111,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. RiverPark Advisors LLC bought a new position in shares of Natera during the 4th quarter valued at $27,000. Harvest Fund Management Co. Ltd bought a new stake in Natera during the third quarter valued at about $44,000. CWM LLC increased its position in Natera by 224.4% in the third quarter. CWM LLC now owns 1,317 shares of the medical research company's stock worth $58,000 after buying an additional 911 shares in the last quarter. Captrust Financial Advisors raised its stake in shares of Natera by 186.4% in the second quarter. Captrust Financial Advisors now owns 2,248 shares of the medical research company's stock worth $80,000 after buying an additional 1,463 shares during the period. Finally, PNC Financial Services Group Inc. raised its stake in shares of Natera by 215.2% in the first quarter. PNC Financial Services Group Inc. now owns 2,049 shares of the medical research company's stock worth $83,000 after buying an additional 1,399 shares during the period. Institutional investors own 99.90% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on NTRA shares. Piper Sandler increased their target price on shares of Natera from $70.00 to $110.00 and gave the stock an "overweight" rating in a report on Wednesday, March 6th. Canaccord Genuity Group lifted their target price on shares of Natera from $87.00 to $100.00 and gave the company a "buy" rating in a research note on Thursday, February 29th. StockNews.com downgraded shares of Natera from a "hold" rating to a "sell" rating in a report on Thursday, March 14th. Raymond James cut Natera from a "strong-buy" rating to an "outperform" rating and raised their price target for the company from $68.00 to $85.00 in a report on Tuesday, February 20th. Finally, The Goldman Sachs Group upped their price objective on Natera from $80.00 to $90.00 and gave the stock a "buy" rating in a research note on Thursday, February 29th. One analyst has rated the stock with a sell rating and fourteen have given a buy rating to the stock. According to data from MarketBeat.com, Natera currently has a consensus rating of "Moderate Buy" and a consensus price target of $85.73.

Natera Price Performance

Shares of NASDAQ NTRA traded down $2.24 during mid-day trading on Friday, hitting $94.47. 959,947 shares of the company's stock traded hands, compared to its average volume of 1,486,340. The company has a market capitalization of $11.41 billion, a P/E ratio of -25.01 and a beta of 1.37. Natera, Inc. has a 1 year low of $36.90 and a 1 year high of $98.82. The company has a debt-to-equity ratio of 0.37, a current ratio of 4.10 and a quick ratio of 3.96. The company's 50-day moving average is $83.61 and its two-hundred day moving average is $63.99.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.73) by $0.09. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. The company had revenue of $311.11 million during the quarter, compared to the consensus estimate of $300.38 million. On average, equities analysts anticipate that Natera, Inc. will post -2.35 EPS for the current fiscal year.

Insider Transactions at Natera

In other news, insider Daniel Rabinowitz sold 35,307 shares of the firm's stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $75.09, for a total transaction of $2,651,202.63. Following the transaction, the insider now directly owns 204,218 shares of the company's stock, valued at $15,334,729.62. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, insider Daniel Rabinowitz sold 35,307 shares of the business's stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $75.09, for a total value of $2,651,202.63. Following the completion of the transaction, the insider now owns 204,218 shares of the company's stock, valued at $15,334,729.62. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Jonathan Sheena sold 447 shares of the business's stock in a transaction on Thursday, March 28th. The stock was sold at an average price of $90.22, for a total value of $40,328.34. Following the completion of the transaction, the insider now directly owns 347,731 shares of the company's stock, valued at $31,372,290.82. The disclosure for this sale can be found here. Over the last three months, insiders have sold 366,477 shares of company stock worth $28,552,682. 9.42% of the stock is currently owned by company insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.